Targeting tumor O‐glycosylation modulates cancer–immune‐cell crosstalk and enhances anti‐PD‐1 immunotherapy in head and neck cancer

• Published in: Molecular oncology Vol. 18; no. 2; pp. 350 - 368
• Main Authors: Lin, Mei‐Chun, Chuang, Ya‐Ting, Wu, Hsin‐Yi, Hsu, Chia‐Lang, Lin, Neng‐Yu, Huang, Min‐Chuan, Lou, Pei‐Jen
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.02.2024; John Wiley and Sons Inc; Wiley
• Subjects: Animal models; Animals; Antibodies; Apoptosis; Cancer Immunotherapy; Cell death; Cell Line, Tumor; Cloning; core 1 β1,3‐galactosyltransferase; Cytokines; Cytotoxicity; Drug therapy; Glycosylation; Head & neck cancer; Head and Neck Cancer; Head and Neck Neoplasms - drug therapy; IL‐6; immune checkpoint inhibitor; Immunotherapy; Inflammation; Interleukin 6; Interleukin-6 - metabolism; Interleukins; Itraconazole; Laboratory animals; Ligands; Lymphocytes T; Macrophages; Metastasis; Mice; O‐glycosylation; PD-1 protein; Phenotypes; Plasmids; Polysaccharides - metabolism; Proteasomes; Protein binding; Proteins; Scientific equipment and supplies industry; Secretome; Stromal cells; T cells; Tumor cells; Tumor Microenvironment; Tumors; Viral antibodies; United States; Taiwan; United States > US; O-glycosylation; immune checkpoint inhibitor; itraconazole; head and neck cancer; core 1 β1,3-galactosyltransferase; IL-6

Cells in the tumor microenvironment (TME) communicate via membrane‐bound and secreted proteins, which are mostly glycosylated. Altered glycomes of malignant tumors influence behaviors of stromal cells. In this study, we showed that the loss of core‐1 β1,3‐galactosyltransferase (C1GALT1)‐mediated O‐g...